These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9566104)

  • 21. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.
    Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Breedveld FC; Dijkmans BA;
    Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-77-82. PubMed ID: 17083767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [When to begin rheumatism treatment? Initial combination therapy helps fastest].
    Fath R
    MMW Fortschr Med; 2004 Sep; 146(37):5-6. PubMed ID: 15887691
    [No Abstract]   [Full Text] [Related]  

  • 23. The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine.
    van Vollenhoven RF; Houbiers JG; Buttgereit F; In 't Hout J; Boers M; Leij S; Kvien TK; Dijkmans BA; Szczepański L; Szombati I; Sierakowski S; Miltenburg AM
    Arthritis Rheum; 2010 Feb; 62(2):351-8. PubMed ID: 20112368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy for rheumatoid arthritis: new paradigms of treatment.
    Wilke WS
    Cleve Clin J Med; 1993; 60(2):101-2. PubMed ID: 8095190
    [No Abstract]   [Full Text] [Related]  

  • 25. [Combination therapy in early rheumatoid arthritis: the COBRA study].
    Boers M; Verhoeven AC; van der Linden S
    Ned Tijdschr Geneeskd; 1997 Dec; 141(50):2428-32. PubMed ID: 9555126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients.
    Elkayam O; Yaron M; Zhukovsky G; Segal R; Caspi D
    Rheumatol Int; 1997; 17(2):49-53. PubMed ID: 9266620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prednisone Use and Risk of Mortality in Patients With Rheumatoid Arthritis: Moderation by Use of Disease-Modifying Antirheumatic Drugs.
    Chester Wasko M; Dasgupta A; Ilse Sears G; Fries JF; Ward MM
    Arthritis Care Res (Hoboken); 2016 May; 68(5):706-10. PubMed ID: 26415107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases.
    Ujfalussy I; Koó E; Seszták M; Gergely P
    Z Rheumatol; 2003 Apr; 62(2):155-60. PubMed ID: 12721703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate.
    O'Dell JR
    Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S53-8. PubMed ID: 10589358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salazosulfapyridine-induced hypersensitivity syndrome triggered by methotrexate.
    Teraki Y; Izaki S
    Clin Exp Dermatol; 2009 Oct; 34(7):e287-8. PubMed ID: 19438549
    [No Abstract]   [Full Text] [Related]  

  • 31. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
    Gubar' EE; Bochkova AG; Bunchuk NV
    Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Long-term combination therapy of chronic polyarthritis: methotrexate and parenteral gold].
    Krause D
    Z Rheumatol; 1998 Feb; 57(1):37-40. PubMed ID: 9566106
    [No Abstract]   [Full Text] [Related]  

  • 33. [Drug therapy and malpractice exemplified by combination leflunomide and methotrexate therapy].
    Burgardt C
    Z Rheumatol; 2002 Apr; 61(2):189-90. PubMed ID: 12056298
    [No Abstract]   [Full Text] [Related]  

  • 34. [Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Combinations of conventional disease-modifying antirheumatic agents].
    Schnabel A; Gross WL
    Dtsch Med Wochenschr; 2003 Jan; 128(4):147-9. PubMed ID: 12589584
    [No Abstract]   [Full Text] [Related]  

  • 35. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial.
    de Jong PH; Hazes JM; Barendregt PJ; Huisman M; van Zeben D; van der Lubbe PA; Gerards AH; de Jager MH; de Sonnaville PB; Grillet BA; Luime JJ; Weel AE
    Ann Rheum Dis; 2013 Jan; 72(1):72-8. PubMed ID: 22679301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial.
    Karstila KL; Rantalaiho VM; Mustonen JT; Möttönen TT; Hannonen PJ; Leirisalo-Repo M; Kaipiainen-Seppänen OA; Karjalainen AH; Korpela MM;
    Clin Exp Rheumatol; 2010; 28(1):73-8. PubMed ID: 20346242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy in rheumatoid arthritis: a comment.
    O'Dell JR; Moore GF; Klassen LW
    Rheumatology (Oxford); 1999 Jun; 38(6):577. PubMed ID: 10402083
    [No Abstract]   [Full Text] [Related]  

  • 38. Combination therapy with sulphasalazine and azathioprine.
    Helliwell PS
    Br J Rheumatol; 1996 May; 35(5):493-4. PubMed ID: 8646444
    [No Abstract]   [Full Text] [Related]  

  • 39. [Basic therapeutic combination therapy in chronic polyarthritis: an overview].
    Menninger H
    Z Rheumatol; 1998 Feb; 57(1):25-30. PubMed ID: 9566103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Side effects and management of side effects of methotrexate in rheumatoid arthritis.
    Albrecht K; Müller-Ladner U
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S95-101. PubMed ID: 21044440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.